What is Biocept?
Biocept, Inc. operates at the intersection of biotechnology and precision medicine, specializing in the development and commercialization of sophisticated molecular diagnostic assays. The company's core value proposition lies in its ability to provide physicians with high-fidelity, clinically actionable information for the treatment and monitoring of various oncological conditions. Central to its technological portfolio is the patented Target Selector platform, which facilitates the capture and quantitative analysis of tumor-associated molecular markers.
Beyond its established blood-based liquid biopsy assays, Biocept has demonstrated significant innovation with the CNSide cerebrospinal fluid assay, a specialized tool designed to detect cancer metastasis within the central nervous system. By leveraging its molecular diagnostic infrastructure, the company has also diversified its operational capabilities to include nationwide COVID-19 RT-PCR testing, showcasing its agility in responding to public health demands while maintaining its primary focus on oncology.
How much funding has Biocept raised?
Biocept has raised a total of $96.8M across 12 funding rounds:
Series C
$3.6M
Series D
$2.3M
Debt
$1.2M
Stock Offering
$19M
Share Placement
$9.3M
Stock Offering
$13.3M
Stock Offering
$10M
Multiple Rounds
$26.1M
Series C (2010): $3.6M, investors not publicly disclosed
Series D (2010): $2.3M, investors not publicly disclosed
Debt (2011): $1.2M, investors not publicly disclosed
Stock Issuance/Offering (2014): $19M, investors not publicly disclosed
Share Placement (2017): $9.3M led by Chardan Capital and ROTH Capital Partners
Stock Issuance/Offering (2018): $13.3M, investors not publicly disclosed
Stock Issuance/Offering (2019): $10M, investors not publicly disclosed
Share Placement (2020): $9.2M, investors not publicly disclosed
Share Placement (2020): $6.6M, investors not publicly disclosed
Share Placement (2020): $10.3M, investors not publicly disclosed
Key Investors in Biocept
Needham Capital Partners
Needham & Company is a prominent investment banking and asset management firm that provides comprehensive advisory and transaction services to growth-oriented companies.
Chardan Capital
An investment firm focused on providing strategic capital and financial advisory services to emerging growth companies in the healthcare and technology sectors.
ROTH Capital Partners
A relationship-driven investment bank specializing in the small-cap market, offering capital raising and strategic advisory services to innovative healthcare enterprises.
What's next for Biocept?
With the recent strategic investment, Biocept is well-positioned to deepen its market penetration and refine its diagnostic pipeline. The company's forward-looking strategy centers on the broader adoption of its CNSide assay and the continued optimization of its liquid biopsy offerings. By prioritizing clinical utility and technological precision, Biocept aims to solidify its status as a leader in the molecular diagnostics space.
The current lifecycle stage, characterized by major enterprise-level funding, suggests a shift toward aggressive commercial scaling and potential expansion into new diagnostic frontiers. As the company continues to integrate its proprietary technology into standard clinical workflows, the focus will remain on driving long-term value through sustained innovation and the delivery of critical diagnostic data that improves patient outcomes in complex cancer cases.
